[Experience with cabazitaxel therapy for patients with metastatic castrate resistant prostate cancer in Hungary]
{{output}}
Our aim was to assess the efficacy and adverse effects of cabazitaxel (CBZ), a chemotherapeutic agent that can be administered to patients with metastatic castrate resistant prostate cancer (mCRPC) after docetaxel (DOC) therapy. We retrospectively analyzed dat... ...
